Reduce Adverse Effects

Swiss blood centres with multiple years’ experience with the INTERCEPT™ Blood System have seen a significant decrease in transfusion-associated adverse events.

The Swissmedic Annual Haemovigilance Report for 2014 included these statements:

• ‘Since the pathogen inactivation (PI) process has been implemented for all platelet concentrates (PC) in Switzerland, no additional cases of sepsis due to PC have been reported’
• ‘In addition to reliably preventing septic transfusion reactions, the introduction of the PI process has led to a reduction in the number and severity of non-infection-related transfusion reactions after PC transfusion’

A recent study¹ shows that the cost by adverse event varies between €150 and €22,000. Reducing the number of adverse events can represent a significant cost saving for your hospital.

‘39% drop in reported transfusion reactions after implementation of the INTERCEPT™

Blood System in Switzerland’.

Swissmedic, Annual Haemovigilance Report, 2014

Sources:

1.Berger K, et al., Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates, Onkologie (2013), 36, 53-59